Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.
L&C Bio plans to launch MegaAdipoECM, an injectable skin booster made from donated human fat, targeting 'Ozempic face' and offering a biological alternative to silicone implants, set to launch in late 2027.
Bank of America spends over $250 million annually covering GLP-1 weight loss drugs for employees, accounting for roughly 13% of its $2 billion healthcare budget, CEO Brian Moynihan told CNBC.
Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.
Pennsylvania Üniversitesi araştırmacıları, Ozempic ve Wegovy gibi GLP-1 ilaçlarının saç dökülmesi riskini SGLT-2 ve DPP-4 inhibitörlerine kıyasla daha yüksek buldu. Çalışma, hızlı kilo kaybı ve besin eksikliğinin geçici saç dökülmesine yol açabileceğini belirtiyor.
Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Giyilebilir teknoloji şirketi WHOOP'un araştırması, zayıflama iğnesi kullananlarda kalp ritminde ek yük ve stres oluştuğunu gösterdi. Haftada 30 dakika egzersiz ve ağırlık antrenmanı bu riskleri azaltıyor.
Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.
Novo Nordisk's weight-loss drugs Wegovy and Ozempic are seeing steady sales growth in India, outpacing generic versions. This comes as the frenzy for Indian generics wanes amid a crowded market, with innovators maintaining a steadier growth trajectory.
A growing number of Indian couples are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss before their weddings, driven by societal pressure and social media expectations. Medical professionals express concern over misuse, potential counterfeits, and health risks.
A growing number of individuals are using GLP-1 injections like Ozempic and Mounjaro for rapid weight loss to meet conventional beauty standards for weddings, rather than for genuine health concerns. This trend alarms medical professionals due to potential health risks, counterfeit drugs, and unsustainable results.
Especialistas en nutrición y diabetes advierten sobre el uso irresponsable de fármacos como Ozempic y Mounjaro para tratar la obesidad en redes sociales. Señalan que su uso sin evaluación médica multidisciplinar y receta puede causar efectos secundarios graves, como la pérdida de masa muscular y la recuperación del peso perdido.
Estudo publicado no Journal of the American Heart Association indica que medicamentos da classe dos agonistas do receptor de GLP-1, usados para diabetes tipo 2 e obesidade, reduziram risco de morte, hospitalizações, revascularizações e amputações em pacientes com doença arterial periférica.
Son yıllarda kilo verme amacıyla kullanılan Ozempic gibi zayıflama iğneleriyle hamile kalan kadınların 'Ozempic bebekleri' olarak adlandırılması yeni bir tartışma başlattı. Uzmanlar, kilo kaybının doğurganlığı artırabileceğini belirtirken, ilaçların doğum kontrol haplarının etkisini azaltabileceği ihtimali üzerinde duruyor.
El Dr. López-Nava aboga por un enfoque integral para la obesidad, combinando fármacos como Ozempic con cambios en el estilo de vida. Advierte que los medicamentos son una ayuda temporal y sin modificación de hábitos, el peso se recupera.
O Ministério da Saúde anunciou um estudo para avaliar o uso da semaglutida no SUS. A substância, usada no tratamento de diabetes e obesidade, pode reduzir o apetite e levar à perda de peso. A proposta visa superar a barreira de preço, com a Novo Nordisk oferecendo um desconto de 59%.
Casos de lesão hepática foram registrados em Victoria, Austrália, após o uso de produtos com retatrutida, substância para obesidade e diabetes. Autoridades suspeitam de contaminantes em versões ilegais comercializadas online.
Cornell Üniversitesi araştırmasına göre, Ozempic ve benzeri GLP-1 ilaçları kullanan hanelerde gıda harcamaları ortalama %5,3 azalıyor. En büyük düşüş yüksek kalorili ve işlenmiş gıdalarda görülürken, yoğurt ve meyve gibi ürünlere harcama artıyor.
Die Erpressergruppe FulcrumSec behauptet, Novo Nordisk habe eine Lösegeldzahlung von 25 Mio. USD verweigert, nachdem sie über ein Terabyte an Daten gestohlen hatten. Die Hacker drohen nun mit dem Verkauf der Daten, ziehen aber eine kostenlose Veröffentlichung vor, um andere Unternehmen abzuschrecken.
Grupo hacker FulcrumSec alega ter roubado mais de 700 mil arquivos da Novo Nordisk, incluindo dados de pacientes e funcionários, e ameaça vender as informações após não conseguir extorquir US$ 25 milhões da empresa.
使用“瘦瘦針”藥物“猛健樂”減重成功的網友，出現臉頰凹陷、法令紋加深等“猛健樂臉”困擾。專家指出，這是快速減重導致脂肪流失的必然結果，並提供運動、控制減重速度、精準營養及醫美修復等四種建議。
